X0306 4 2020-07-16 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001700449 Arix Bioscience plc 20 BERKELEY SQUARE MAYFAIR, LONDON X0 W1J6EQ UNITED KINGDOM 0 0 1 0 0001756884 Arix Bioscience Holdings Ltd 20 BERKLEY SQUARE MAYFAIR, LONDON X0 W1J6EQ UNITED KINGDOM 0 0 1 0 Common stock 2020-07-16 4 S 0 16332 8.559 D 2962691 I See footnote Common stock 2020-07-17 4 S 0 31101 9.24 D 2931590 I See footnote Common stock 2020-07-20 4 S 0 36983 9.249 D 2894607 I See footnote Common stock 2020-07-22 4 S 0 22651 9.004 D 2871956 I See footnote Common stock 2020-07-29 4 S 0 2709 8.781 D 2869247 I See footnote Common stock 2020-08-12 4 S 0 1335 8.79 D 2867912 I See footnote Common stock 2020-08-13 4 S 0 159 8.75 D 2867753 I See footnote Common stock 2020-09-24 4 S 0 38514 7.629 D 2829239 I See footnote Common stock 2020-09-25 4 S 0 174219 7.077 D 2655020 I See footnote Common stock 2020-09-28 4 S 0 273584 7.5365 D 2381436 I See footnote Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Arix Bioscience Plc, by: /s/ Marcus Karia, Authorized Officer 2020-10-05 Arix Bioscience Holdings Limited, by: /s/ Marcus Karia, Authorized Officer 2020-10-05